LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Nuveen Asset Management LLC

Nuveen Asset Management LLC decreased its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 10.6% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 53,858 shares of the medical instruments supplier's stock after selling 6,355 shares during the period. Nuveen Asset Management LLC owned about 0.24% of LeMaitre Vascular worth $4,962,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in LMAT. Raymond James Financial Inc. acquired a new stake in shares of LeMaitre Vascular during the fourth quarter valued at $14,900,000. Rockefeller Capital Management L.P. acquired a new stake in LeMaitre Vascular in the 4th quarter worth about $7,787,000. Segall Bryant & Hamill LLC acquired a new stake in LeMaitre Vascular in the 4th quarter worth about $5,446,000. Invesco Ltd. boosted its stake in LeMaitre Vascular by 50.5% in the 4th quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after buying an additional 58,720 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in LeMaitre Vascular by 96.8% in the 4th quarter. Millennium Management LLC now owns 96,081 shares of the medical instruments supplier's stock worth $8,853,000 after buying an additional 47,250 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

Wall Street Analyst Weigh In

LMAT has been the topic of a number of research analyst reports. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price target on the stock. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Oppenheimer downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Finally, Lake Street Capital raised their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $97.83.

LeMaitre Vascular Stock Performance

Shares of NASDAQ:LMAT traded down $0.31 during mid-day trading on Wednesday, hitting $82.55. 101,781 shares of the company traded hands, compared to its average volume of 168,743. The firm has a market cap of $1.87 billion, a P/E ratio of 45.11, a PEG ratio of 2.22 and a beta of 0.86. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58. The firm's 50 day simple moving average is $83.75 and its 200 day simple moving average is $91.44.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.02). The company had revenue of $59.87 million for the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business's quarterly revenue was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.44 earnings per share. Equities research analysts expect that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were issued a dividend of $0.20 per share. The ex-dividend date was Thursday, May 15th. This represents a $0.80 annualized dividend and a dividend yield of 0.97%. LeMaitre Vascular's payout ratio is currently 40.40%.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total transaction of $164,979.08. Following the sale, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. The trade was a 26.53% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO George W. Lemaitre sold 4,399 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $85.10, for a total value of $374,354.90. Following the sale, the chief executive officer now owns 1,827,003 shares in the company, valued at $155,477,955.30. This represents a 0.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 102,009 shares of company stock worth $8,721,836. 9.50% of the stock is currently owned by company insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.